DavalosDAkassoglouK.Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol2012; 34(1): 43–62.
2.
MarikCFeltsPABauerJ, et al. Lesion genesis in a subset of patients with multiple sclerosis: A role for innate immunity. Brain2007; 130(Pt 11): 2800–2815.
3.
PetersenMARyuJKAkassoglouK.Fibrinogen in neurological diseases: Mechanisms, imaging and therapeutics. Nat Rev Neurosci2018; 19(5): 283–301.
4.
VercellinoMMaseraSLorenzattiM, et al. Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J Neuropathol Exp Neurol2009; 68(5): 489–502.
5.
YatesRLEsiriMMPalaceJ, et al. Fibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex. Ann Neurol2017; 82(2): 259–270.
6.
DavalosDRyuJKMerliniM, et al. Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat Commun2012; 3: 1227.
7.
HanMHHwangSIRoyDB, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature2008; 451(7182): 1076–1081.
8.
RyuJKPetersenMAMurraySG, et al. Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation. Nat Commun2015; 6: 8164.
9.
AdamsRABauerJFlickMJ, et al. The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med2007; 204(3): 571–582.
10.
RyuJKRafalskiVAMeyer-FrankeA, et al. Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat Immunol2018; 19(11): 1212–1223.
